(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

https://doi.org/10.1007/s00705-021-04956-9

NCT04351295-This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.